^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Thrombopoietin receptor agonist

    Related drugs:
    3d
    A multicenter, prospective, phase II clinical study of hytrombopag ethanolamine tablets combined with immunosuppressive therapy in newly diagnosed patients with non-severe aplastic anemia (ChiCTR2600117565)
    P=N/A, N=76, Not yet recruiting, Tianjin Medical University General Hospital; Tianjin Medical University General Hospital
    New trial
    3d
    Single-center clinical study on the efficacy and safety of romiplostim N01 in promoting platelet engraftment after hematopoietic stem cell transplantation (ChiCTR2600116939)
    P=N/A, N=88, Not yet recruiting, The First Affiliated Hospital of Guilin Medical University; The First Affiliated Hospital of Guilin Medical University
    New trial
    |
    NKG2D (killer cell lectin like receptor K1)
    |
    Nplate (romiplostim) • Rui Lisheng (romiplostim biosimilar)
    3d
    A Single-Arm, Multicenter, Exploratory Study on the Efficacy and Safety of Romiplostim NO1 in Platelet Recovery After Autologous Hematopoietic Stem Cell Transplantation (ChiCTR2500114483)
    P=N/A, N=50, Not yet recruiting, The First Affiliated Hospital of Bengbu Medical University; The First Affiliated Hospital of Bengbu Medical University
    New trial
    |
    CD34 (CD34 molecule)
    |
    Nplate (romiplostim) • Rui Lisheng (romiplostim biosimilar)
    3d
    A Prospective Multicenter Randomized Controlled Clinical Study on the Efficacy and Safety ofRomiplostim (N01) in the Prevention ofThrombocytopenia after Chemotherapy for Childhood Tumors (ChiCTR2500114006)
    P=N/A, N=120, Not yet recruiting, The First Affiliated Hospital,Sun Yat-sen University; The First Affiliated Hospital,Sun Yat-sen University
    New trial
    |
    Nplate (romiplostim)
    3d
    Efficacy of Avatrombopag in Primary/Secondary Prevention of ADC Drug-Induced Thrombocytopenia in Breast Cancer (ChiCTR2500112156)
    P=N/A, N=72, Not yet recruiting, Fujian Cancer Hospital; Fujian Cancer Hospital
    New trial
    |
    Herceptin (trastuzumab)
    3d
    A prospective, single-arm study of romiplostim N01 for prevention of chemotherapy-induced thrombocytopenia in patients with non-Hodgkin's lymphoma (ChiCTR2600116402)
    P4, N=30, Not yet recruiting, Jiangxi Cancer Hospital; Jiangxi Cancer Hospital
    New P4 trial
    |
    Nplate (romiplostim) • Rui Lisheng (romiplostim biosimilar)
    3d
    A Multicenter, Single-Arm Study of Romiplostim N01 in Megakaryocytic Engraftment after Allogeneic Hematopoietic Stem Cell Transplantation for Bone Marrow Failure Diseases (ChiCTR2600116641)
    P4, N=35, Not yet recruiting, The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University
    New P4 trial
    |
    Nplate (romiplostim) • Rui Lisheng (romiplostim biosimilar)
    3d
    Efficacy and Safety of Herombopag Ethanolamine Tablets in Combination with Cyclosporine and Androgen for the Treatment of Transfusion-Dependent Non-Severe Aplastic Anemia (TD-NSAA) Patients—A Single-Arm, Prospective, Multicenter Phase II Clinical Study (ChiCTR2500114419)
    P4, N=42, Recruiting, West China Hospital of Sichuan University; West China Hospital of Sichuan University
    New P4 trial
    |
    cyclosporine
    3d
    High-Dose Romiplostim (N01) Monotherapy for Aplastic Anemia with Specific Gene Mutations: A Prospective Clinical Study (ChiCTR2600117237)
    P3, N=60, Not yet recruiting, The First Affiliated Hospital of Zhejiang Chinese Medical University; The First Affiliated Hospital of Zhejiang Chinese Medical University
    New P3 trial
    |
    Nplate (romiplostim)
    3d
    A Clinical Study Comparing Romiplostim and rhTPO for Platelet Engraftment after Umbilical Cord Blood Transplantation (ChiCTR2500115443)
    P2, N=60, Not yet recruiting, TThe Seventh Affiliated Hospital of Sun Yat-sen University (Shenzhen); The Seventh Affiliated Hospital of Sun Yat-sen University (Shenzhen)
    New P2 trial
    |
    Nplate (romiplostim)
    3d
    A Multicenter, Single-Arm Exploratory Clinical Study on the Efficacy and Safety of Herombopag Olamine Tablets in Patients with Breast Cancer Experiencing Thrombocytopenia Induced by T-DM1 (ChiCTR2500112127)
    P2, N=56, Recruiting, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    New P2 trial
    |
    Kadcyla (ado-trastuzumab emtansine)
    7d
    Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer (clinicaltrials.gov)
    P3, N=145, Active, not recruiting, Amgen | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Nplate (romiplostim)